Literature DB >> 10344528

G protein coupling of CGS 21680 binding sites in the rat hippocampus and cortex is different from that of adenosine A1 and striatal A2A receptors.

R A Cunha1, M D Constantino, J A Ribeiro.   

Abstract

The effect of guanine nucleotide-binding protein (G protein) modifiers on the binding of the adenosine A2A receptor agonist 2-[4-(2-p-carboxyethyl[3H])phenyl-amino]-5'-N-ethylcarboxamidoadenosine ([3H]CGS 21680) and of the adenosine A1 receptor agonist [3H]R-phenylisopropyladenosine ([3H]R-PIA) to rat cortical and striatal membranes was studied. Guanosine 5'-(beta,gamma-imido)triphosphate (1-300 microM), which uncouples all G proteins, more effectively inhibited [3H]CGS 21680 (30 nM) binding in the cortex than [3H]R-PIA (2 nM) binding to cortical or striatal membranes or [3H]CGS 21680 (30 nM) binding in the striatum. N-Ethylmaleimide (1-300 microM) or pertussis toxin (1-100 microg/ml), which uncouple G(i)/G(o) protein-coupled receptors, more effectively inhibited [3H]R-PIA binding to cortical or striatal membranes and [3H]CGS 21680 binding in the cortex than [3H]CGS 21680 binding in the striatum. Cholera toxin (2.5-250 microg/ml), which uncouples G(S) protein-coupled receptors, more effectively inhibited [3H]CGS 21680 binding in the striatum than [3H]CGS 21680 binding in the cortex and less effectively inhibited [3H]R-PIA binding to cortical or striatal membranes. Treatment of solubilised cortical membranes with pertussis toxin (50 microg/ml) decreased [3H]CGS 21680 (30-100 nM) binding which almost fully recovered after reconstitution with G(i)/G(o) proteins. The K(i) for displacement of [2-3H]-(4{2-[7-amino-2-(2-furyl)(1,2,4)triazolo(2,3-a)(1,3,5)triazin+ ++-5-ylamino]ethyl}phenol) ([3H]ZM 241385, 1nM) by CGS 21680 was 110 nM (95%CI: 98-122 nM) in non-treated, 230 (167-292) nM in pertussis toxin (25 microg/ml)-treated and 222 (150-295) nM in cholera toxin (50 microg/ml)-treated cortical membranes; in contrast, the K(i) for displacement of [3H]-5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazol o(1,5-c)pyrimidine ([3H]SCH 58261, 1 nM) by CGS 21680 was 74 (57-91) nM in non-treated, 71 (44-100) nM in pertussis toxin-treated and 147 (100-193) nM in cholera toxin-treated cortical membranes. Finally, CGS 21680 displaced monophasically the binding of the A1 antagonist, [3H]8-cyclopentyl-1,3-dipropylxanthine (2 nM), and the A1 agonist, [3H]R-PIA (2 nM), in 2 or 10 mM Mg(2+)-medium, either at 25 degrees C or 37 degrees C, in cortical or striatal membranes. These results indicate that CGS 21680 does not bind to A1 receptors and that limbic CGS 21680 binding sites differ from striatal-like A2A receptors since they couple to G(i)/G(o) proteins, as well as to G(s) proteins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10344528     DOI: 10.1007/pl00005355

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  9 in total

1.  Regulation of hippocampal cannabinoid CB1 receptor actions by adenosine A1 receptors and chronic caffeine administration: implications for the effects of Δ9-tetrahydrocannabinol on spatial memory.

Authors:  Vasco C Sousa; Natália Assaife-Lopes; Joaquim A Ribeiro; Judith A Pratt; Ros R Brett; Ana M Sebastião
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

2.  Binding of adenosine receptor ligands to brain of adenosine receptor knock-out mice: evidence that CGS 21680 binds to A1 receptors in hippocampus.

Authors:  Linda Halldner; Luisa V Lopes; Elisabetta Daré; Karin Lindström; Björn Johansson; Catherine Ledent; Rodrigo A Cunha; Bertil B Fredholm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-18       Impact factor: 3.000

3.  Release inhibitory receptors activation favours the A2A-adenosine receptor-mediated facilitation of noradrenaline release in isolated rat tail artery.

Authors:  Paula Fresco; Carmen Diniz; Glória Queiroz; Jorge Gonçalves
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

4.  Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists.

Authors:  Ming Yang; Daniel Soohoo; Sandriyana Soelaiman; Rao Kalla; Jeff Zablocki; Nancy Chu; Kwan Leung; Lina Yao; Ivan Diamond; Luiz Belardinelli; John C Shryock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-20       Impact factor: 3.000

5.  Adenosine A(2A) receptors in portal hypertension: their role in the abnormal response to adenosine of the cranial mesenteric artery in rabbits.

Authors:  M T Villa de Brito; A Canto; J H Duarte Correia; R A Cunha; M C Marques
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

Review 6.  Purinergic signaling in the retina: From development to disease.

Authors:  Ana Lucia Marques Ventura; Alexandre Dos Santos-Rodrigues; Claire H Mitchell; Maria Paula Faillace
Journal:  Brain Res Bull       Date:  2018-11-17       Impact factor: 4.077

7.  Binding of the prototypical adenosine A(2A) receptor agonist CGS 21680 to the cerebral cortex of adenosine A(1) and A(2A) receptor knockout mice.

Authors:  Luísa V Lopes; Linda Halldner; Nelson Rebola; Björn Johansson; Catherine Ledent; Jian Fan Chen; Bertil B Fredholm; Rodrigo A Cunha
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

8.  Adenosine A2A Receptor: A New Neuroprotective Target in Light-Induced Retinal Degeneration.

Authors:  Manuel Soliño; Ignacio M Larrayoz; Ester María López; Manuel Rey-Funes; Mariana Bareiro; Cesar Fabián Loidl; Elena Girardi; Alfredo Martínez; Juan José López-Costa
Journal:  Front Pharmacol       Date:  2022-03-21       Impact factor: 5.810

Review 9.  International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.

Authors:  Adriaan P IJzerman; Kenneth A Jacobson; Christa E Müller; Bruce N Cronstein; Rodrigo A Cunha
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.